Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37695
Volltext verfügbar? / Dokumentlieferung
Titel: Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer : Results from the International Robotic Cystectomy Consortium
VerfasserIn: Gopalakrishnan, Dharmesh
Elsayed, Ahmed S.
Hussein, Ahmed A.
Jing, Zhe
Li, Qiang
Wagner, Andrew A.
Aboumohamed, Ahmed
Roupret, Morgan
Balbay, Derya
Wijburg, Carl
Stöckle, Michael
Dasgupta, Prokar
Khan, Muhammad Shamim
Wiklund, Peter
Hosseini, Abolfazl
Peabody, James
Shigemura, Katsumi
Trump, Donald
Guru, Khurshid A.
Chatta, Gurkamal
Sprache: Englisch
Titel: International Journal of Urology
Bandnummer: 29 (2022)
Heft: 3
Seiten: 197-205
Verlag/Plattform: Wiley
Erscheinungsjahr: 2021
Freie Schlagwörter: bladder cancer
chemotherapy
muscle-invasive
neoadjuvant
oncological outcomes
recurrence
recurrences
robot-assisted radical cystectomy
survival
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Objectives To analyze the impact of neoadjuvant chemotherapy on survival and recurrence patterns in muscle-invasive bladder cancer after robot-assisted radical cystectomy. Materials and methods The International Robotic Cystectomy Consortium database was reviewed to identify patients who underwent robot-assisted radical cystectomy for muscle-invasive bladder cancer between 2002 and 2019. Survival outcomes, response rates, and recurrence patterns were compared between patients who received neoadjuvant chemotherapy and those who did not. Survival distributions were estimated using Kaplan–Meier analyses and compared using the log-rank test. Results A total of 1370 patients with muscle-invasive bladder cancer were identified, of whom 353 (26%) received neoadjuvant chemotherapy. After a median follow-up of 27 months, neoadjuvant chemotherapy recipients had higher 3-year overall survival (74% vs 57%; log-rank P < 0.01), 3-year cancer-specific survival (83% vs 73%; log-rank P = 0.03), and 3-year relapse-free survival (64% vs 48%; log-rank P < 0.01). Neoadjuvant chemotherapy was a predictor of higher overall survival, cancer-specific survival, and relapse-free survival in univariate but not multivariate analysis. Pathological downstaging (46% vs 23%; P < 0.01), complete responses (24% vs 8%; P < 0.01), and margin negativity (95% vs 91%; P < 0.01) at robot-assisted radical cystectomy were more common in the neoadjuvant chemotherapy group. Neoadjuvant chemotherapy recipients had lower distant (15% vs 22%; P < 0.01) but similar locoregional (12% vs 13%; P = 0.93) recurrence rates. Conclusions In this analysis from a large international database, patients with muscle-invasive bladder cancer who received neoadjuvant chemotherapy before robot-assisted radical cystectomy had higher rates of survival, pathological downstaging, and margin-negative resections. They also experienced fewer distant recurrences.
DOI der Erstveröffentlichung: 10.1111/iju.14749
URL der Erstveröffentlichung: https://onlinelibrary.wiley.com/doi/10.1111/iju.14749
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-376954
hdl:20.500.11880/34100
http://dx.doi.org/10.22028/D291-37695
ISSN: 1442-2042
0919-8172
Datum des Eintrags: 25-Okt-2022
Bezeichnung des in Beziehung stehenden Objekts: Supporting Information
In Beziehung stehendes Objekt: https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Fiju.14749&file=iju14749-sup-0001-Supinfo.docx
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Urologie und Kinderurologie
Professur: M - Prof. Dr. Michael Stöckle
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Es gibt keine Dateien zu dieser Ressource.


Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt.